超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

普洛股份 Apeloa Kangyu
普洛股份有限公司（證券簡稱：普洛股份；股票代碼： 000739）是一家主要從事醫(yī)藥中間體、化學(xué)原料藥及制劑、天然藥物的生產(chǎn)、經(jīng)營、研發(fā)的上市公司。

公司現(xiàn)擁有浙江普洛康裕制藥有限公司98%的股權(quán)、浙江普洛得邦化學(xué)有限公司86%的股權(quán)、浙江普洛醫(yī)藥科技有限公司95.7%的股權(quán)，浙江普洛康裕天然藥物有限公司90%的股權(quán)，上海普洛藥物研究有限公司62%的股權(quán)。憑借各控股子公司科學(xué)靈活的經(jīng)營機制、強大的生產(chǎn)能力、對科研與市場突出的整合能力，普洛康裕股份有限公司已一舉成為國內(nèi)醫(yī)藥行業(yè)具有相當(dāng)規(guī)模和重大影響力的大型企業(yè)，并向國際化企業(yè)邁進。

Apeloa Kangyu is a reputed pharmaceutical company in China, engaging in R&D, manufacturing and marketing of APIs, formulations and veterinary drugs. It's dedicated to supplying high quality chemical synthesis products and biological synthesis products.

Apeloa Kangyu owns two GMP certified and US FDA approved facilities, and have passed OSHAS18001, ISO14001 and ISO9001 certifications. The products' DMF are available, and 4 products (Ofloxacin, Colistin Sulfate, Pseudoephedrine HCl, Simvastatin) are granted with COS and most products are successfully registered in other countries.

Apeloa Kangyu has become a most dynamic and reliable pharmaceutical company in China, because of its good reputation on satisfying customers' expectations on guaranteed supply, high quality, competitive price, excellent service and strict information confidentiality.